Ardaman Shergill, MD, University of Chicago, Chicago, IL, talks on the role of first-line EFGR antibodies in patients with metastatic RAS wild-type colorectal cancer. The Phase III PARADIGM (NCT02394795) and STRATEGIC-1 (NCT01910610) trials received anti-EFGR therapies in later line settings, which necessitates further research in the potential efficacy of first-line anti-EFGR antibodies. Significant clinical toxicity and financial considerations observed in existing studies, such as the CAIRO5 study (NCT02162563), suggests that anti-EFGR agents are preferable in pretreated patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ